Tag Archives: financial markets

Fewer Small Public Biotechs Today

Fig2-size-2008-vs-2013-115x76

A lot can happen in six years. The number of active biotech companies currently trading on US exchanges is now only 300. At the start of 2008, there were almost 400 active companies.   The net decrease in the number of active companies since 2008 is 24%. Had it not been for all the IPO activity we have seen this year, the decrease would have been substantially more. In fact, only 55% of the original Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Prosensa’s IPO and the Value of the BIO Investor Forum

Hans Schikan

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Our primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. We completed an IPO onto NASDAQ in June of this year. Prior to last year’s BIO Investor Forum in San Francisco, we were still in the very Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

The Burrill Report: Pushing Policies in a Changed Washington

The Burrill Report’s Daniel Levine talks to BIO’s Alan Eisenberg regarding recent fluctuations in the financial markets and the impact on public policy. Eisenberg discusses implementation of BIO’s legislative proposals and the outlook for the industry. BIO will be hosting the BIO Investor Forum to bring together industry leaders to discuss these recent developments that could have a major influence in helping to shape the future of biotechnology.

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,